optima-logo.png
Opthea Presents Phase 1/2a Data of OPT-302 in wet AMD at the Retina Society 2018 Annual Meeting
September 14, 2018 05:30 ET | Opthea Limited
MELBOURNE, Australia, Sept. 14, 2018 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a late stage clinical biopharmaceutical company developing first-in-class novel biologic therapies to treat...
optima-logo.png
Opthea Receives Positive Interim Review from Independent Safety Committee in Phase 2b Wet AMD Clinical Trial
September 05, 2018 05:30 ET | Opthea Limited
MELBOURNE, Australia, Sept. 05, 2018 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a late stage biopharmaceutical company developing novel biologic therapies to treat back-of-the eye diseases, today...
optima-logo.png
Opthea Doses First Patient in Phase 2a Trial for OPT-302 in Diabetic Macular Edema
July 30, 2018 06:00 ET | Opthea Limited
MELBOURNE, Australia, July 30, 2018 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a late stage biopharmaceutical company developing novel biologic therapies to treat back-of-the eye diseases, has...
optima-logo.png
Opthea Meets Primary Safety Objective with OPT-302 in Phase 1b Diabetic Macular Edema Clinical Trial
July 26, 2018 05:30 ET | Opthea Limited
MELBOURNE, Australia, July 26, 2018 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a late stage biopharmaceutical company developing novel biologic therapies to treat back-of-the eye diseases,...
optima-logo.png
Opthea’s Phase 2b Wet AMD Clinical Trial Reaches Mid-Way Point of Patient Recruitment
July 02, 2018 05:30 ET | Opthea Limited
MELBOURNE, Australia, July 02, 2018 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a late stage biopharmaceutical company developing novel biologic therapies to treat back-of-the eye diseases, is...
optima-logo.png
Opthea Doses Patients in Europe and Israel in Phase 2b Study of OPT-302 for Wet AMD
March 27, 2018 05:30 ET | Opthea Limited
MELBOURNE, Australia, March 27, 2018 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a developer of novel biologic therapies for the treatment of eye diseases, has dosed the first patients in Europe...
Phase 1b/2a Clinical Trial Summary
Opthea Initiates OPT-302 Diabetic Macular Edema Clinical Trial
January 03, 2018 05:30 ET | Opthea Limited
MELBOURNE, Australia, Jan. 03, 2018 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a late stage biopharmaceutical company developing novel biologic therapies to treat back-of-the-eye diseases, has...
Opthea Doses First Patient in Phase 2b Study of OPT-302 for Wet AMD
December 19, 2017 05:30 ET | Opthea Limited
MELBOURNE, Australia, Dec. 19, 2017 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a developer of novel biologic therapies for the treatment of eye diseases, announced today the dosing of the first...